

ISSUE @ A GLANCE



Mechanisms of heart failure with preserved ejection fraction, risk stratification of heart failure with reduced ejection fraction, and new light on resistance to diuretics in acute decompensated heart failure
F. Crea 4405

CardioPulse

A tribute to Attilio Maseri
F. Crea, E. Braunwald, and V. Fuster 4410

The anticoagulation grey zone
M. Nicholls 4412

ESC 2021 Gold Medal recipients
M. Nicholls 4415

Weekly Journal Scan

Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?
G. Liuzzo and C. Patrono 4418

STATE OF THE ART REVIEW

Heart Failure and Cardiomyopathies




Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models

C. Withaar, C.S.P. Lam, G.G. Schiattarella, R.A. de Boer, and L.M.G. Meems 4420



Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction

A. Sinha, H. Rahman, A. Webb, A.M. Shah, and D. Perera 4431




FAST TRACK CLINICAL RESEARCH

Heart Failure and Cardiomyopathies

Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial

C.S.P. Lam, J.P. Ferreira, E. Pfarr, D. Sim, H. Tsutsui, S.D. Anker, J. Butler, G. Filippatos, S.J. Pocock, N. Sattar, S. Verma, M. Brueckmann, J. Schnee, D. Cotton, F. Zannad, and M. Packer

4442



Editorial

A fourth pillar for all in the treatment of heart failure

E.F. Lewis

4452

Heart Failure and Cardiomyopathies

Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial

S.J. Pocock, J.P. Ferreira, J. Gregson, S.D. Anker, J. Butler, G. Filippatos, N.D. Gollop, T. Iwata, M. Brueckmann, J.L. Januzzi Jr, A.A. Voors, F. Zannad, and M. Packer

4455

Editorial

Biomarker-driven prognostic model for risk prediction in heart failure: ready for Prime time?

D. Wussler and C. Mueller

4465

CLINICAL RESEARCH

Heart Failure and Cardiomyopathies

Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure

Z.L. Cox, V.S. Rao, J.B. Ivey-Miranda, J. Moreno-Villagomez, D. Mahoney, P. Ponikowski, J. Biegus, J.M. Turner, C. Maulion, L. Bellumkonda, J.L. Asher, H. Parise, P.F. Wilson, D.H. Ellison, C.S. Wilcox, and J.M. Testani

4468

Editorial

Renal sodium avidity, the prevailing renal target in heart failure

P. Martens, W.H.W. Tang, and W. Mullens

4478

TRANSLATIONAL RESEARCH

Heart Failure and Cardiomyopathies

Glucosylceramide synthase deficiency in the heart compromises β 1-adrenergic receptor trafficking

L. Andersson, M. Cinato, I. Mardani, A. Miljanovic, M. Arif, A. Koh, M. Lindbom, M. Laudette, E. Bollano, E. Omerovic, M. Klevstig, M. Henricsson, P. Fogelstrand, K. Swärd, M. Ekstrand, M. Levin, J. Wikström, S. Doran, T. Hyötyläinen, L. Sinisalu, M. Orešič, Å. Tivesten, M. Adiels, M.O. Bergo, R. Proia, A. Mardinoglu, A. Jeppsson, J. Borén, and M.C. Levin

4481

Editorial

Assembling fats and sugar for cardiac protection

J.-L. Balligand and L.Y.M. Michel

4493

DISCUSSION FORUM

Efficacy of the Biosync trial, or when facts prompt a reconsideration of theories

J.G. van Dijk, F.J. de Lange, and R. Sutton

4496

Efficacy of the Biosync trial: the information published from this trial to date is not sufficient to change theory

W. Wieling and D.L. Jardine

4497

About syncopal recurrences in Biosync trial

M. Brignole

4499

CARDIOVASCULAR FLASHLIGHT



Myocardial microthrombi after COVID-19 mRNA vaccination

T. Aikawa, J. Ogino, Y. Kita, and N. Funayama


4501



Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site

<https://academic.oup.com/eurheartj>



www.eurheartj.org